Volume 28, Number 7—July 2022
Research
Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021–February 2022
Mircea T. Sofonea, Bénédicte Roquebert, Vincent Foulongne, David Morquin, Laura Verdurme, Sabine Trombert-Paolantoni, Mathilde Roussel, Jean-Christophe Bonetti, Judith Zerah, Stéphanie Haim-Boukobza, and Samuel Alizon
Table 2
Results of ID Solution Revolution SARS-CoV-2 variant-specific screening tests (N = 193,256), France, December 18, 2021–February 28, 2022*
| Characteristic | Value |
|---|---|
| Age of patient, y, median (95% CI) |
36 (6–74) |
| Context | |
| General population | 187,292 (96.9) |
| Hospital |
5,964 (3.1) |
| Region | |
| Ile-de-France | 40,185 (20.8) |
| Hauts-de-France | 26,382 (13.7) |
| Normandie | 31,205 (16.2) |
| Nouvelle-Aquitaine | 13,236 (6.9) |
| Provence-Alpes-Côte d’Azur | 31,299 (16.2) |
| Occitanie | 9,034 (4.7) |
| Corse | 8,031 (4.2) |
| Bourgogne-Franche-Comté | 4,366 (2.3) |
| Grand Est | 6,865 (3.6) |
| Centre-Val de Loire | 10,412 (5.4) |
| Bretagne | 9,405 (4.9) |
| Other |
2,836 (1.5) |
| Outcome | |
| A0B9C1D0 | 12,955 (6.7) |
| A0B9C0D1 | 154,134 (79.8) |
| A0B9C1D1 | 173 (0.1) |
| A1B9C0D0 | 4,762 (2.5) |
| Other | 21,232 (10.9) |
*Values are no. (%) patients except as indicated.
Page created: May 03, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.